BriaCell Therapeutics Corp 8-K, filed Mar 9, 2026
BriaCell Therapeutics Corp. (BCTX)
About this 8-K
BriaCell Therapeutics Corp filed this 8-K on March 9, 2026, reporting on events of March 5, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| British Columbia | ||
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Commission
File No.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered under Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07 Submission of Matters to a Vote of Security Holders
On March 5, 2026, BriaCell Therapeutics Corp. (the “Company”) held its Annual General and Special Meeting of Shareholders (the “Meeting”). As of January 26, 2026, the date of record for determining the shareholders entitled to vote on the proposals presented at the Meeting, there were 7,250,487 common shares of the Company issued and outstanding and entitled to vote at the Meeting. A total of 3,502,695 common shares of the Company, constituting a quorum, were represented in person or by valid proxies at the Meeting. The matters submitted to a vote of the Company’s shareholders at the Meeting are described in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on February 12, 2026. The final results for each of the matters submitted to a vote of the Company’s shareholders at the Meeting are as follows:
Proposal 1. At the Meeting, the shareholders ratified the appointment of MNP LLP as auditors for the Company and the authorization of the Board of Directors of the Company (the “Board”) to fix the auditors’ remuneration and terms of engagement. The result of the votes to ratify the appointment of MNP LLP was as follows:
| For | Withhold | Broker Non-Votes | ||
| 3,431,761 | 70,934 | 0 |
Proposal 2. At the Meeting, the terms of six (6) members of the Board expired. Each of the six (6) nominees for director (the “Nominees”) were elected to serve until the next annual and special meeting of shareholders, or until his/her successor is duly elected or appointed, unless he/she resigns, is removed, or becomes disqualified in accordance with the Articles of the Company, as amended and in effect, or the Business Corporations Act (British Columbia). The result of the votes to elect the Nominees was as follows:
| Directors | For | Withhold | Broker Non-Votes | |||
| Dr. Jane Gross | 1,837,220 | 49,810 | 1,615,665 | |||
| Mr. Jamieson Bondarenko | 1,847,842 | 39,188 | 1,615,665 | |||
| Dr. William V. Williams | 1,837,675 | 49,355 | 1,615,665 | |||
| Dr. Rebecca Taub | 1,837,729 | 49,301 | 1,615,665 | |||
| Mr. Vaughn C. Embro-Pantalony | 1,847,644 | 39,386 | 1,615,665 | |||
| Mr. Martin Schmieg | 1,844,132 | 42,898 | 1,615,665 |
Proposal 3. At the Meeting, the Company’s shareholders re-approved the Company’s omnibus equity incentive plan (the “Omnibus Equity Incentive Plan”). The result of the votes to re-approve the Omnibus Equity Incentive Plan was as follows:
| For | Against | Broker Non-Votes | ||
1,524,081 |
362,949 | 1,615,665 |
EXHIBIT INDEX
| Exhibit | Description | |
| 10.1 | Omnibus Equity Incentive Plan (incorporated by reference from Schedule I to the Definitive Proxy Statement on Schedule 14A of the Company, filed with the SEC on February 12, 2026). | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BRIACELL THERAPEUTICS CORP. | |
| /s/ William V. Williams | |
| March 9, 2026 | William V. Williams |
| President and Chief Executive Officer |